* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
We provide a variety of targeted degradation strategy development services based on the lysosomal pathway, covering multiple degradation needs such as transmembrane proteins, extracellular proteins, and antibody endocytosis targets, which are widely used in basic research, drug target verification, protein function research, and new drug development. We focus on lysosomal-based targeted degradation technology to help basic research and drug development. Services range from technical consultation, construction design to in vitro and in vivo functional verification to meet customers' personalized scientific research and transformation needs.
Request a Consultation Explore ServicesLysosomes play a vital role in the degradation and recycling of extracellular material and in maintaining cell homeostasis. Lysosomes function in two ways, endocytosis for extracellular material and autophagy for intracellular material. Lysosomes contain various hydrolytic enzymes which can break down proteins, nucleic acids, polysaccharides, lipids, etc.
Lysosome-based targeted protein degradation is an emerging therapeutic and research strategy that harnesses the cell's natural lysosomal pathway to selectively degrade unwanted or disease-associated proteins-particularly those located on the cell surface or in the extracellular space. Unlike proteasome-based systems such as PROTACs, which primarily target intracellular proteins, lysosome-mediated approaches enable the degradation of membrane-bound and secreted proteins, dramatically expanding the scope of druggable targets.
At its core, this strategy involves tagging the target protein with a molecule (such as an antibody or ligand) that can recruit cellular receptors capable of initiating endocytosis. Once internalized, the tagged protein is trafficked to lysosomes, which are acidic organelles equipped with hydrolases that break down biological macromolecules.
Fig 1. The lysosomal degradation pathway (Pei, 2021)
Targets extracellular and transmembrane proteins that are inaccessible to proteasomal degradation.
Utilizes endogenous cellular pathways such as receptor-mediated endocytosis (e.g., CI-M6PR, ASGPR) or autophagy.
Compatible with various formats including antibodies, small molecules, peptides, and chimeric degraders (e.g., LYTACs, AUTACs).
Enables selective and potent degradation without requiring genetic manipulation.
Objective: Support clients in evaluating whether target proteins are suitable for lysosome-based degradation pathways.
Objective: Develop customized LYTAC molecules using antibodies or ligands to degrade membrane proteins.
Objective: Design and identify small molecules capable of recruiting target proteins to the lysosomal degradation pathway.
Objective: Construct bispecific antibodies that link target proteins to lysosomal degradation pathways.
Objective: Identify and leverage specific endocytic receptors (e.g., ASGPR, CI-M6PR, TfR) to enhance intracellular delivery efficiency.
Objective: Verify degradation molecule activity and underlying mechanisms through cellular assays.
Objective: Provide large-scale primary screening and validation for small molecule degraders.
Objective: Generate supportive data for preclinical and clinical development.
Objective: Provide end-to-end project solutions from target discovery to IND filing.
We offer end-to-end technical capabilities across all major lysosome-based degradation platforms, including LYTAC, AUTAC, ATTEC, and AbTAC. Our team is experienced in choosing and optimizing the most appropriate modality based on target location, structure, and cellular context.
Whether it's bifunctional small molecules or antibody-ligand conjugates, we provide fully customized design services. This includes ligand sourcing, linker chemistry, conjugation strategy, and receptor targeting for efficient internalization and lysosomal delivery.
Our team has deep expertise in designing degraders that leverage various lysosomal targeting receptors such as CI-M6PR, ASGPR, and transferrin receptor. We tailor receptor-ligand systems based on your target cell type to ensure optimal uptake and degradation efficiency.
We provide comprehensive cell-based validation services, including degradation kinetics (e.g., CHX chase), lysosomal colocalization imaging, and downstream functional assays. You receive robust data demonstrating proof of mechanism and efficacy.
From standalone design or synthesis to complete hit-to-lead or IND-enabling studies, we support flexible collaboration models. We can serve as a strategic CRO partner or scientific co-developer, depending on your project needs and timeline.
Our streamlined workflows and deep scientific bench allow for fast, responsive project execution. Every project is guided by PhD-level scientists with expertise in chemical biology, immunology, and targeted degradation.
We offer a fully integrated, stepwise workflow tailored to your project needs-whether you are developing a LYTAC, AUTAC, ATTEC, AbTAC, or other lysosome-targeting modality.
Target Assessment
Protein profiling
Degradation fit
Strategy suggestion
Feasibility report
Molecule Design
Degrader types
Ligand synthesis
Antibody linkage
In Vitro
Internalization
Trafficking
Degradation test
Mechanism probe
Mechanism Validation
Pathway readout
Kinetics
Dependency check
In Vivo (Optional)
Animal models
PK/Distribution
Degradation assay
Safety profile
Data Transfer
Report delivery
IP support
Tech transfer
Targeting EGFR, PD-L1, LAMP2, and Other Cell Surface Proteins
Lysosome-based technologies like LYTAC and AbTAC enable selective degradation of membrane proteins such as EGFR, PD-L1, and LAMP2 for applications in cancer and metabolic diseases.
Targeting Misfolded Proteins Like α-Synuclein, TDP-43, and Tau
ATTEC and AUTAC platforms promote the removal of misfolded proteins like α-synuclein, TDP-43, and Tau in neurodegenerative disease research.
Regulating Mitophagy via Parkin, PINK1, and LC3
Lysosome-driven strategies regulate mitophagy through Parkin, PINK1, and LC3 to eliminate damaged mitochondria in metabolic and cardiovascular disorders.
Designing Lysosome-Targeted Conjugates and Receptor-Mediated Uptake Pathways
LYTAC and AbTAC enable targeted drug delivery via lysosome-targeting conjugates and receptor-mediated uptake mechanisms like ASGPR and CI-M6PR.
Discovering Degradable Targets and Assessing Compound Efficacy
Lysosomal pathways support high-throughput drug screening and validation by identifying degradable targets and assessing compound efficacy.
1. What types of proteins can be targeted using lysosome-based degradation technologies?
Lysosome-based approaches, such as LYTAC and AbTAC, are ideal for targeting extracellular and membrane-bound proteins. Newer modalities like ATTEC and AUTAC also enable intracellular protein clearance by leveraging autophagy pathways.
2. How do I choose between LYTAC, AUTAC, ATTEC, and AbTAC?
The choice depends on your target protein's location, structure, and biological context. For example, LYTACs are best for membrane proteins with accessible extracellular domains, while AUTAC/ATTEC are better suited for intracellular targets. Our scientific team will help evaluate your target and recommend the most suitable platform.
3. Do you offer end-to-end service, or can I outsource specific parts (e.g., molecule synthesis only)?
Yes, we offer flexible collaboration. You can engage us for complete end-to-end services (from design to validation), or for specific modules such as ligand screening, antibody conjugation, or in vitro degradation assays.
4. Is this technology suitable for therapeutic development?
Yes. Lysosome-targeted degradation platforms are being actively explored for drug development, particularly in oncology, immunology, and neurodegenerative diseases. Our workflow includes translational support and preclinical validation options to bridge discovery and therapeutic development.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Please contact us with any specific requirements and we will get back to you as soon as possible.